- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07832370
A Trial of ALN-6457 in Adult Participants With Symptomatic Prion Disease (PrD)
Phase 1/2 Open-Label Trial With Extended Follow-Up to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Multiple Doses of ALN-6457 in Participants With Symptomatic Prion Disease
This study will test a Regeneron drug called ALN-6457 ("study drug") to see if it can help treat Prion Disease (PrD).
In PrD, the prion protein folds into an abnormal shape. These abnormal proteins build up in the brain and cause damage to brain cells, leading to problems with thinking, memory, and movement.
ALN-6457 is designed to reduce the amount of prion protein made in the brain. ALN-6457 works by targeting the genetic "instructions" that cells use to produce this protein, with the goal of slowing or stopping disease progression.
This study is looking at:
- What side effects ALN-6457 might cause
- How well ALN-6457 works
- What is the best dose of ALN-6457 for treating prion disease
- How much ALN-6457 is in the blood and Cerebrospinal Fluid (CSF, fluid that surrounds the brain and spinal cord) at different times
Studieoversigt
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiekontakt
- Navn: Clinical Trials Administrator
- Telefonnummer: 844-734-6643
- E-mail: clinicaltrials@regeneron.com
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
-
Participant must meet all of the criteria under either:
- sporadic CJD as described in the protocol or
- genetic PrD, as described in the protocol
-
Has a Body Mass Index (BMI) <35 kg/m2 (inclusive) at the screening visit
-
Able to understand and complete trial-related questionnaires at screening
Key Exclusion Criteria:
- Clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric or neurological disease (excluding prion disease) that, as assessed by the investigator, may confound the results of the trial or pose an additional risk to the participant during trial participation
- Medical history of brain or spinal disease/injury that would interfere with the Lumbar Puncture (LP) procedure or CSF circulation, as described in the protocol
- Any contraindications to undergo a brain Magnetic Resonance Imaging (MRI)
- An established allergy or intolerance to local anesthetics
- Current history of bleeding diatheses that would increase risk of bleeding upon LP
- Any malignancy that is progressing or requires active treatment, as described in the protocol
- Attempted suicide, suicidal ideation with a plan that required hospital admission and/or change in level of care within 12 months prior to screening
NOTE: Other Protocol-Defined Inclusion/Exclusion Criteria Apply.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Dosiseskalering
|
Administered per the protocol
Andre navne:
|
|
Eksperimentel: Cohort Expansion
|
Administered per the protocol
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Occurrence of Treatment Emergent Adverse Events (TEAEs)
Tidsramme: Through Week 156
|
Through Week 156
|
|
Severity of TEAEs
Tidsramme: Through Week 156
|
Through Week 156
|
|
Percentage change in concentration of Neurofilament Light chain (NfL) in plasma from baseline
Tidsramme: Through Week 130
|
Through Week 130
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Concentration of Prion Protein (PrP) in CSF
Tidsramme: Through Week 130
|
Through Week 130
|
|
Change from baseline in concentration of PrP in CSF
Tidsramme: Through Week 130
|
Through Week 130
|
|
Concentration of ALN-6457 and its major metabolites in plasma
Tidsramme: Through Week 130
|
Through Week 130
|
|
Concentration of ALN-6457 and its major metabolites in CSF
Tidsramme: Through Week 130
|
Through Week 130
|
|
Overall survival rate
Tidsramme: At Week 52
|
At Week 52
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Clinical Trial Management, Regeneron Pharmaceuticals
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
- Proteinfejlfoldningslidelse
- Neurodegenerativ sygdom
- Demens
- Sygdom i centralnervesystemet
- Infektioner i centralnervesystemet
- PrD
- Symptomatic Prion Disease
- Sporadic Prion Disease
- Genetic Prion Disease
- Inherited Prion Disease
- Familial Prion Disease
- Gerstmann-Straussler-Scheinker syndrome (GSS)
- Fatal familial insomnia (FFI)
- Rapidly-Progressive Dementia
- Creutzfeldt-Jakob Disease (CJD)
- Fatal Familial Insomnia
- Prion-Associated Disorder
- Prion-Induced Disorder
- Neurological Decline
- Transmissible Spongiform Encephalopathy
Yderligere relevante MeSH-vilkår
- Hjernesygdomme
- Sygdomme i nervesystemet
- Psykiske lidelser
- Genetiske sygdomme, medfødte
- Metaboliske sygdomme
- Infektioner
- Neurokognitive lidelser
- Søvnvågningsforstyrrelser
- Heredodegenerative lidelser, nervesystem
- Søvnforstyrrelser, iboende
- Dyssomnier
- Søvninitiering og vedligeholdelsesforstyrrelser
- Medfødte, arvelige og neonatale sygdomme og abnormiteter
- Ernæringsmæssige og metaboliske sygdomme
- Demens
- Neurodegenerative sygdomme
- Sygdomme i centralnervesystemet
- Proteostase mangler
- Creutzfeldt-Jakob syndrom
- Infektioner i centralnervesystemet
- Søvnløshed, Fatal Familie
- Prionsygdomme
- Gerstmann-Straussler-Scheinker-sygdom
Andre undersøgelses-id-numre
- ALN-6457-PD-25129
- 2026-526727-21-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing.
IPD-delingstidsramme
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD-delingsadgangskriterier
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .